Completed PHASE2 INTERVENTIONAL NCT00189358

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Sponsor: AGO Study Group

Conditions Cancer of the Fallopian Tube Ovarian Cancer Peritoneal Cancer

Updated 7 times since 2017 Last updated: Jul 19, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cancer of the Fallopian Tube and Ovarian Cancer, this trial is completed. The trial is conducted by AGO Study Group and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Study Group

Data source: AGO Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Düsseldorf, Germany